Floatz logo

Alpelisib

PIK3CA Mutated Advanced Solid Tumors

Novartis PharmaceuticalsSmall moleculePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the PIK3CA Mutated Advanced Solid Tumors cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G, ANTI-(HUMAN INSULIN-LIKE GROWTH FACTOR I RECEPTOR) (HUMAN MONOCLONAL HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL LIGHT CHAIN, DIMER
Novartis Pharmaceuticals
Phase 1/2CC

Same molecule, other indications

Alpelisib is also rated in:

triple-negative breast carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
HER2 positive breast carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
Sickle Cell AnemiaDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →